PF-06763809
- Generic Name
- PF-06763809
Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03469336
- Locations
- 🇩🇪
bioskin GmbH, Hamburg, Germany
🇩🇪Rothaar Studien GmbH, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath